Ibrutinib

Ibrutinib

Anticancer Drug (Carboxamide derivative)

Blood cancer (Chronic lymphocytic leukemia)

Mechanism of Action

Ibrutinib is a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an integral component of the B-cell receptor (BCR) and cytokine receptor pathways. Constitutive activation of B-cell receptor signaling is important for survival of malignant B-cells; BTK inhibition results in decreased malignant B-cell proliferation and survival.

Contact Us